Nateglinide-d5

Nateglinide-d5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

Product Specifications

CAS Number

[1227666-13-8]

Product Name Alternative

A4166 D5; Senaglinide D5

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Dipeptidyl Peptidase; Potassium Channel

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Purity

98.0

Solubility

10 mM in DMSO|DMSO : 100mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](CC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])NC([C@H]2CC[C@H](C(C)C)CC2)=O

Molecular Formula

C19H22D5NO3

Molecular Weight

322.45

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3) : 6.|[2]Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.|[3]Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62 (1) :90-9.|[4]Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568 (1-3) :278-86.